What Enflurane Treats: Main Uses and Benefits

Enflurane is commonly used to provide supportive symptomatic relief for patients undergoing medical and surgical procedures. It is applied in situations where short-term, profound symptomatic support is relevant. The medication is commonly used in contexts involving general anesthesia, and is considered relevant for managing acute pain associated with childbirth.

Relief of Awareness, Pain, and Memory During Surgical Procedures

In clinical practice, the management of conscious awareness, memory formation, and acute pain is addressed during surgical operations. This is relevant for patients in situations that require the relief of acute sensory and psychological distress associated with surgical intervention.

Management of Involuntary Movement and Protective Reflexes

Enflurane is applied to manage disruptive motor and reflex manifestations, including involuntary movements and protective reflexes like gagging or coughing. This application supports physical stillness which is relevant for the clinical needs during the procedure.

“The application is relevant for managing symptoms related to increased neurological or muscular activity.”

Symptomatic Support in Acute Obstetric Scenarios

The medication is considered relevant for easing symptoms related to intense, acute pain associated with specific, time-limited clinical events, such as pain experienced during active labor and delivery. By offering short-term relief from pain symptoms, Enflurane provides supportive relief that helps patients cope more steadily and comfortably with the heightened discomfort of the obstetric phase.

Quick Fact: Relief for Acute Distress

Who can and cannot use Enflurane?

Population eligibility for Enflurane is strictly defined by regulatory documents, which establish mandated exclusions and conditional use categories.

Eligibility Scope

Eligibility Classifications (High-Level)

Official regulatory documents primarily classify eligibility as Contraindicated (e.g., MH susceptibility), Warning (e.g., neuromuscular disease), or Caution (e.g., individualized dosage for the elderly). The most severe restrictions focus on genetic predisposition, prior adverse reactions to similar agents, and pre-existing convulsive disorders. Use is conditionally permitted for adults and in specific, low-concentration obstetric settings.

Enflurane can interact with several other medications, primarily by affecting the central nervous system (CNS), cardiovascular system, and neuromuscular function. It's essential to inform your healthcare provider about all medicines you are taking, including over-the-counter products and supplements, before receiving enflurane.

Potential Drug Interactions

Enflurane can also increase the cardiodepressant effects of drugs like Amiodarone. The concurrent use of Epinephrine (adrenaline) and other sympathomimetics during enflurane anesthesia requires caution due to the potential for cardiac arrhythmias, although the risk is generally considered low when used in limited doses. High concentrations of enflurane may cause uterine relaxation and increase bleeding risk when used during obstetric procedures, an effect that can diminish the response to Oxytocin (a drug used to contract the uterus).

Enflurane is a volatile anesthetic agent that exerts its effects primarily within the central nervous system. Its principal molecular targets include GABA A receptors and potassium channels. Enflurane acts as a positive allosteric modulator at the GABA A receptor complex. This interaction potentiates the inhibitory effect of the endogenous neurotransmitter gamma-aminobutyric acid (GABA), increasing the frequency and duration of chloride ion channel opening. The resulting influx of Cl^- ions induces hyperpolarization of the postsynaptic neuron membrane, decreasing neuronal excitability and signal transmission across synapses. Concurrently, Enflurane modulates certain two-pore-domain potassium channels ( K2 P channels, such as TREK-1), promoting their open state. The outward flux of K^+ ions contributes to cellular hyperpolarization. These actions collectively suppress neuronal firing in structures including the cerebral cortex, thalamus, and hippocampus. The intracellular consequence of widespread neuronal inhibition manifests system-level modulation, including reduced cerebral metabolic rate and dose-dependent suppression of central circulatory and respiratory drive.

Enflurane is a general anesthetic supplied as a volatile liquid that is administered exclusively via inhalation. This method mandates the use of a calibrated anesthetic vaporizer to accurately convert the liquid into a breathable vapor, ensuring controlled delivery of the concentration to the patient's breathing circuit. Given the requirements for continuous adjustment and monitoring, its use is restricted to an adequately equipped medical setting under the constant supervision of personnel trained in general anesthesia.

Administration Patterns and Concentration Ranges

The use of Enflurane is defined by continuous, short-term administration throughout the surgical or obstetric procedure. The concentration in the inspired air must be continually adjusted—or titrated—to meet the specific needs of the patient during the intervention.

Dosage requirements are also subject to adjustment for specific populations. For instance, the effective concentration needed to produce anesthesia generally decreases with increasing age. Additionally, when used as a supplement for Cesarean section, low concentrations are specified to mitigate administration constraints associated with uterine contractility.

Enflurane: Recent Clinical Evidence

Evidence for Use in General Anesthesia

The primary research base for Enflurane includes large-scale Randomized Controlled Trials (RCTs) and multicenter studies. This body of evidence was used in research exploring the achievement and maintenance of a controlled state of unconsciousness and immobility for surgical procedures. These studies included populations of both Adults and Children undergoing various operations.

Research examined how quickly the desired anesthetic state was reached and how rapidly patients returned to consciousness afterwards. Trials monitored several post-anesthetic recovery characteristics, such as the time required for a patient to awaken or the total time until extubation. The findings describe patterns observed in these studies when Enflurane was compared to other volatile anesthetic agents available at the time. Research documented short-term changes measured during the study period, including assessments of immediate outcomes following the procedure.

What remains uncertain is the relative difference between Enflurane and other similar agents regarding very rare, severe surgical outcomes. Because the incidence of these outcomes (like heart attack or stroke) was very low across all groups in large comparative trials, the available research provides limited insight into establishing relative differences in these specific rare events. Furthermore, this evidence contributes to the broader evidence landscape but is primarily derived from older clinical trials, and its direct relevance to newer anesthetic agents is limited to historical comparative data.

Evidence for Use in Obstetric Analgesia

Separate clinical studies were conducted to evaluate the use of low concentrations of Enflurane vapor for providing symptomatic relief from acute pain during the active phase of labor and vaginal delivery. Research examined the experience of Parturients (women in labor).

In these studies, researchers monitored outcomes related to maternal analgesia, such as the patient's level of cooperation and consciousness during the delivery process. Trials also monitored measurements of neonatal status after delivery, such as Apgar scores and neurobehavioral assessments. Findings describe patterns observed when Enflurane was compared to other agents used for obstetric pain relief, such as nitrous oxide. Research documented how symptoms evolved in the observed populations, and contributed to understanding short-term changes for both mother and child during and immediately following delivery.

The evidence for this specific application is primarily based on older clinical studies, and few recent investigations have been conducted. The established relationship between higher concentrations and increased uterine bleeding means research on its full dose range in this specific population is limited.

Long-Term Evidence and Follow-up in Research

Research exploring short-term symptom changes was observed in studies with follow-up durations that focused heavily on the immediate recovery period, typically ranging from the time of surgery up to 30 minutes afterward. For assessing general post-operative outcomes, studies monitored responses over defined time intervals, sometimes extending up to several days (for example, seven days).

There is limited information for long-term outcomes that track patients for extended periods (months or years) after receiving Enflurane. The current evidence primarily addresses the acute and short-term post-operative phase, meaning long-term effects are not fully established.

Evidence in Specific Patient Populations

The primary research for this medicine was evaluated in broad populations, allowing for subgroup analysis of certain patient types. The evidence includes studies for Adults undergoing general surgery. Separate clinical research explored outcomes in the Children population for various procedures. The specific use for pain relief during labor led to research being conducted on Parturients (women in labor).

Overall, results apply only to the populations studied. Data for certain groups, such as those with specific severe comorbid conditions, may remain insufficient, as is common with general anesthetic agents whose primary focus is the immediate surgical context.

What Research Still Considers Uncertain

While a large amount of comparative data exists, certain areas remain uncertain. As noted, there is limited information for long-term outcomes beyond the immediate post-operative window. The evidence quality varies across studies, particularly between the older historical trials and more modern comparative studies.

Furthermore, as Enflurane was studied for use in a specific concentration range during labor and delivery due to observed effects at higher levels, research concerning its full potential dose range in this specific population remains insufficient. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References

1. Enflurane analgesia in obstetrics (Comparative study vs. Nitrous Oxide)

Common questions about Enflurane (FAQ)

Q: Can Enflurane be used for women in labor and delivery?

According to the official product information, Enflurane is approved for use to provide analgesia (pain relief) during vaginal delivery. Its primary uses also include the induction and maintenance of general anesthesia.

Q: Does the use of Enflurane affect the baby when used for delivery analgesia?

Studies and official information indicate that Enflurane is classified as Pregnancy Category B, meaning animal studies have not shown harm to the fetus. However, the label cautions that using high concentrations can be associated with an effect on the uterus, potentially leading to uterine relaxation and increased uterine bleeding.

Q: How quickly does a patient wake up after receiving Enflurane?

The experience of recovery after receiving a general anesthetic like Enflurane varies based on several factors, including the length of the procedure. Official data suggests that a slight, temporary decrease in intellectual function may be noted for two to three days after the anesthesia is stopped, and small changes in mood may also persist for several days.

Q: Can patients with kidney problems be given Enflurane?

The breakdown of Enflurane creates inorganic fluoride in the body. Regulatory information states that the resulting fluoride levels are generally low, typically below the amount that may cause minimal kidney damage. However, it is noted that renal failure (kidney failure) has been reported as a potential complication associated with Malignant Hyperthermia.

Q: What is 'Malignant Hyperthermia,' and is there a risk of it with Enflurane?

Malignant Hyperthermia is a rare, severe reaction where muscles enter a hypermetabolic state. Official warnings state that Enflurane may trigger this syndrome in individuals who are genetically susceptible. For this reason, susceptibility to Malignant Hyperthermia is listed as a contraindication (a condition where the drug should not be used).

Q: Is it true that Enflurane is associated with changes in brain electrical activity (EEG)?

Changes in brain electrical activity, specifically a convulsive pattern on an electroencephalogram (EEG), have been reported as a possible adverse reaction. This is particularly noted with deeper levels of anesthesia.

Q: What exactly is Enflurane used for in a hospital setting?

Enflurane is approved for use in the hospital setting for two main purposes: the induction (starting) and maintenance (keeping) of general anesthesia during surgical procedures, and providing analgesia (pain relief) during vaginal delivery.

Q: Are there any long-term side effects associated with Enflurane use?

Official information notes that effects are generally short-lived. A slight decrease in intellectual function may persist for two to three days following administration. Small changes in mood and symptoms may also continue for several days after the anesthetic is stopped.

Q: What are the most common side effects reported during or after Enflurane administration?

During the administration phase, common side effects can include agitation, coughing, breath holding, and laryngospasm (voice box spasm). Side effects frequently reported during recovery include nausea, vomiting, and chills/shivering.

Q: Can Enflurane cause nausea and vomiting after surgery?

Yes, nausea and vomiting are listed among the most common adverse reactions reported in official documents during the recovery phase after receiving Enflurane.

Q: Is there a risk of fever or high body temperature from Enflurane?

A significant increase in body temperature is a sign of Malignant Hyperthermia, a serious adverse event that Enflurane may trigger in susceptible people. In addition, fever and chills/shivering are also listed as possible side effects reported by patients.

Q: What happens if a patient has a history of seizures and is given Enflurane?

Official warnings advise that Enflurane should be used with caution in patients who may be more susceptible to the cortical stimulation the drug can produce. This includes patients with a history suggesting an increased risk for seizure activity.

Q: Is Enflurane known to affect the heart or blood pressure?

Yes, Enflurane is known to affect the heart and circulatory system. It is associated with a dose-dependent decrease in blood pressure. The heart rate generally remains relatively constant during anesthesia.

Q: Can Enflurane cause liver damage or affect liver enzyme levels?

Official documents mention that mild, moderate, or severe liver injury, including rare cases of hepatic failure, may follow anesthesia. An increase in liver enzyme levels (serum transaminases) has also been observed in some cases.

Q: Does Enflurane interact negatively with common blood pressure or heart medications?

Yes, official drug interaction lists mention that Enflurane may increase the activity of certain heart and blood pressure medications. This includes drugs like beta-blockers and other antihypertensive agents (blood pressure reducers).

Q: Which types of drugs are known to interact with Enflurane?

Interactions are noted for several drug classes. These include antihypertensive agents, neuromuscular blockers (muscle relaxants), oxytocics, cholinesterase inhibitors, and those with central nervous system (CNS) depressant effects, such as some sedative medications.

Q: Is there a risk of breathing problems or difficulty breathing after using Enflurane?

Yes, official documents list respiratory adverse reactions such as cough, breath holding, and laryngospasm as common. Respiratory depression has also been reported.

Q: Can Enflurane be used safely in pediatric patients (children)?

Pediatric patients are listed in official documents as a population where special caution is advised. For young children, official warnings related to inhaled anesthetics suggest that the potential benefits must be weighed against possible risks.

Q: Is Enflurane suitable for patients with a known history of hepatitis or liver conditions?

Official documents list a history of hepatic disease (liver disease) as a contraindication for the use of Enflurane, meaning the drug should generally not be used in this population.

Q: Does Enflurane have a specific smell or odor?

Before being vaporized for inhalation, Enflurane is described in official documents as a clear, colorless liquid that has a mild, sweet odor.

Q: Is there a risk of confusion or memory problems after receiving Enflurane?

Confusion, delirium, and a temporary decrease in intellectual function are among the adverse reactions reported. The label notes that a slight decrease in intellectual function may persist for two to three days.

Q: Does Enflurane cause a change in heart rhythm?

Yes, official documents list various types of cardiac arrhythmias (changes in heart rhythm), including ventricular, nodal, and atrial, as possible adverse reactions reported with the use of the drug.

Q: Can Enflurane cause an allergic reaction?

Signs consistent with a severe allergic reaction, such as hives, swelling of the face or throat, and difficulty breathing, have been reported in post-marketing experience. Cross-sensitization—a reaction to a different, but similar anesthetic—is also a possibility noted in some official information.

Q: What is the 'MAC' value, and how does it relate to Enflurane?

MAC stands for Minimum Alveolar Concentration, which is a scientific measurement used to describe the potency (strength) of an inhaled anesthetic. For Enflurane in pure oxygen, the MAC value is listed in official documents as 1.68%.

Q: Why are there warnings about combining Enflurane with some sedative medications?

Official drug interaction data indicates that combining Enflurane with certain medications that act as sedatives (like benzodiazepines) can increase the risk or severity of central nervous system (CNS) depression, which can affect breathing and consciousness.

Q: Can people who are allergic to other anesthetics be given Enflurane?

Due to the possibility of cross-sensitization between similar types of anesthetics (specifically, halogenated agents), a history of a reaction to another anesthetic is a factor used to assess the risk of an allergic response.

Q: Are there any specific pre-existing conditions that prevent a person from receiving Enflurane?

Official documents list known susceptibility to Malignant Hyperthermia and a history of hepatic (liver) disease as contraindications. There are also official warnings to use caution in patients with a history of seizures.

Q: Does Enflurane cause throat or airway irritation?

Yes, adverse reactions affecting the airway such as cough, breath holding, and laryngospasm (spasm of the vocal cords or voice box) are listed as commonly reported, particularly during the induction phase of anesthesia.

Q: Does Enflurane make you feel drowsy or tired in the 24 hours after a procedure?

Adverse reactions reported after the procedure include drowsiness, asthenia (weakness), and fatigue. These effects may contribute to feeling tired or lacking energy in the hours following the procedure.

Q: What is the physical appearance of Enflurane before it is vaporized?

Before it is converted into a gas for inhalation by the vaporizer, Enflurane is described in official documentation as a clear, colorless liquid.

Q: Can Enflurane interact with herbal supplements or over-the-counter pain relievers?

The label for Enflurane includes interaction information for certain non-prescription medications. For example, it is noted that Enflurane may increase the potential hepatotoxic (liver damage) activities of acetaminophen.

Q: Is there any research on the use of Enflurane in pregnant patients?

Enflurane is classified as Pregnancy Category B. Official documents state that reproduction studies in animals have not shown harm to the fetus, but there are no adequate and well-controlled studies conducted in pregnant women.

Q: Does Enflurane affect the body's control over breathing rate?

Yes, official documents state that respiratory depression (slowed or shallow breathing) has been reported. This is due to the dose-dependent suppression of the central respiratory drive that controls breathing.

Q: Is Enflurane safe to use in older or elderly patients?

Older (elderly) patients are listed as a population where special precautions are noted for its use. Official labeling indicates that the required dose of Enflurane generally decreases with increasing age to achieve the desired effect.

Q: What is the significance of the breakdown product 'inorganic fluoride' related to Enflurane?

The metabolism of Enflurane in the body creates a substance called inorganic fluoride. The resulting fluoride levels are generally low, with official documents noting that they are typically below the level that may cause minimal kidney damage.

Q: Can Enflurane be used for pain relief other than for labor and delivery?

The only analgesic indication (pain relief) listed in official documents is for providing pain relief during vaginal delivery. Its other approved use is for the induction and maintenance of general anesthesia.

Official Storage and Disposal Requirements

Enflurane is defined in regulatory documents as a clear, colorless liquid with high chemical stability. The product is inherently stable, does not require added stabilizers, and is resilient to decomposition from strong bases, ultraviolet light, or contact with soda lime. It is supplied in glass bottles and is classified as a nonflammable liquid. Consistent with all potent medicines, Enflurane must be stored out of the sight and reach of children.

Disposal is governed by strict pharmaceutical waste regulations. Any unused or expired liquid Enflurane must be managed as hazardous waste. Empty containers can be treated as non-hazardous waste after defacing the label. Furthermore, waste anesthetic gases require an approved scavenging system, and related materials like used charcoal canisters must be handled as hazardous chemical waste.